Lenacapavir is the first medicine of an entirely new class, a capsid inhibitor, and the first antiretroviral that can be given as an injection only twice a year. It is used for multidrug-resistant HIV and has been studied extensively as long-acting prevention.
What is the HIV capsid?
The cone-shaped protein shell that encloses the virus's genetic material. For a long time it was regarded as inert packaging. It turns out to be an active participant: it has to assemble correctly, protect the genome, transport it to the cell nucleus and then disassemble at exactly the right moment.
How does lenacapavir work?
It binds to the capsid protein and interferes with several of those steps simultaneously. Assembly is disrupted, transport into the nucleus is impaired, and disassembly happens at the wrong time. Because it interferes at multiple points in the life cycle, the virus struggles to escape it through a single change.
Why does a new class matter?
Because resistance to lenacapavir does not overlap with resistance to any existing drug. Someone whose virus has defeated nucleoside analogues, non-nucleosides, protease inhibitors and integrase inhibitors may still respond fully to it. For people with extensive resistance, that is the difference between having options and not.
What is it licensed for?
Its established use is in combination with other antiretrovirals for adults with multidrug-resistant HIV whose current regimen is failing. This is a small group with few remaining choices, and it is where the drug was first approved.
What about prevention?
It has been studied extensively as pre-exposure prophylaxis with striking results. Availability for prevention in the UK has been developing and varies by area, so your clinic is the place to ask what is currently commissioned rather than relying on anything you have read.
Why can it last six months?
Because of both the molecule and the formulation. It is highly potent, so a small amount goes a long way, and it has poor water solubility, so a subcutaneous injection forms a depot under the skin that dissolves extremely slowly. Together these allow twice-yearly dosing.
Where is it injected?
Under the skin of the abdomen, usually as two injections at the same appointment, given by a healthcare professional. This differs from cabotegravir, which goes into the gluteal muscle.
Why are tablets involved at the start?
Because the injection takes time to establish useful levels. An initiation schedule combining tablets and injections covers the first days or weeks, after which the injection alone maintains the level. The exact sequence differs between the treatment and prevention uses.
Is it used alone?
For treatment, no: it is given alongside other antiretrovirals chosen on the basis of resistance testing. For prevention, it is used alone, as PrEP normally is, which makes HIV testing before every injection essential.
How new is it?
It reached clinical use in the early 2020s, so experience is shorter than with most drugs on this site. The trial data are strong and the long-term real-world picture is still accumulating, which is worth bearing in mind rather than treating it as fully characterised.
Who is it suited to?
For treatment, people with extensive resistance and few remaining options. For prevention, people for whom even a two-monthly injection is difficult, or who want the fewest possible interactions with services. Two appointments a year is the lowest burden of any option available.
Does it prevent anything else?
No. It covers HIV only, with no activity against hepatitis B or anything else transmitted sexually. Because injections are only twice yearly, the three-monthly screening for other infections has to be arranged separately and is easy to overlook.
Where does it sit against the alternatives?
No antiretroviral is best in every situation. What matters is the fit between the drug and your kidney function, your other medicines, your hepatitis status, your resistance history and how you actually live. That is a conversation with a clinician rather than a ranking.